Cancer is designated as a reportable disease in the state of Utah (Cancer Reporting Rule, R384-100).
The Utah Cancer Registry collects diagnostic information, treatment, and follow-up in accordance with data standards of the National Cancer Institute SEER Program, the North American Association of Central Cancer Registries, and the National Program of Cancer Registries.
Cancer cases are identified through systematic review of:
- pathology reports
- medical records
- hospital discharge lists
- and vital records
How to Report Cancer Cases
For details about reporting cancer cases to Utah Cancer Registry, please refer to the following:
In accordance with the National Cancer Institute SEER Program and the National Program of Cancer Registries guidelines, cases reportable to the registry follow the SEER Program Coding and Staging Manual 2021.
For a summary of reportable conditions, see below. For detailed reportability requirements, refer to SEER Program Coding and Staging Manual 2021 beginning on page 6. To access historical versions of staging and coding manuals for diagnosis years prior to 2021, please visit the SEER Website.
In situ and malignant/invasive histologies (Behavior code /2, /3, see ICD-O-3) are reportable including:
- Early or evolving melanoma, in situ and invasive: As of 01/01/2021, early or evolving melanoma in situ, or any other early or evolving melanoma, is reportable.
- All GIST tumors are reportable as of 01/01/2021.
- Nearly all thymomas are reportable as of 01/01/2021. The exceptions are:
- Microscopic thymoma or thymoma, benign (8580/0)
- Micronodular thymoma with lymphoid stroma (8580/1)
- Ectopic hamartomatous thymoma (8587/0)
- Carcinoid, NOS of the appendix is reportable. As of 01/01/2015, the ICD-O-3 behavior code changed from /1 to /3.
- Intraepithelial neoplasia, grade III (examples: AIN III C210 & C211; VAIN III & VIN III)
- Lobular carcinoma in situ (LCIS) of breast
- Urine cytology positive for malignancy is reportable for diagnoses in 2013 and later (exception: When a subsequent biopsy of a urinary site is negative, do not report)
- Non-invasive mucinous cystic neoplasm (MCN) of the pancreas with high grade dysplasia
- Mature teratoma of the testes in adults is malignant and reportable as 9080/3
- Benign and borderline primary intracranial and central nervous system (CNS) tumors with a behavior code /0 or /1) in ICD-O-3 (effective with cases diagnosed 01/01/2004 to 12/31/2020) or ICD-O-3.2 (effective with cases diagnosed 01/01/2021 and later). Refer to table in SEER Programing Coding and Staging Manual 2021 page 8 for specific sites.
Note: Benign and borderline primary intracranial tumors and pituitary adenomas have been reportable per state reporting requirements since the inception of the Utah Cancer Registry in 1966.
- Pilocytic Juvenile astrocytoma is reportable and should be coded as 9421 with behavior /3 (9421/3)
- Neoplasms and tumor are reportable terms for intracranial and CNS because they are listed in ICD-O-3.2 with behavior codes of /0 and /1
- "Mass" and "lesion" are not reportable terms for intracranial and CNS because they are not listed in ICD-O-3.2 with behavior codes of /0 or /1
Malignant and invasive histologies which are not required:
- Do not report skin primaries (C440-C449) with any of the following histologies:
- Malignant neoplasm (8000-8005)
- Epithelial carcinoma (8010-8046)
- Papillary and squamous cell carcinoma (8050-8084)
- Basal cell carcinoma (8090-8110)
- AIN III (8077) arising in perianal skin (C445)
- Do not report carcinoma in situ of cervix (/2) or cervical intraepithelial neoplasia (CIN III or SIN III) of the cervix (as of January 1, 1996)
- Do not report prostatic intraepithelial neoplasia (PIN III) of the prostate (C619) (as of January 1, 2001)
See the reportability section of the SEER Program Coding and Staging Manual 2021 beginning on page 6 for a more descriptive list of reportable diagnoses and exceptions.